Memogain (GLN-1062) is primarily investigated for its potential therapeutic applications in neurodegenerative disorders, particularly Alzheimer's disease. It is believed to enhance cognitive function by modulating cholinergic activity, which is crucial for memory and learning processes. The compound may also exhibit neuroprotective properties, helping to slow the progression of neuronal damage. Research focuses on its ability to improve symptoms such as memory loss and cognitive decline, making it a promising candidate for treating conditions associated with aging and dementia. Clinical studies aim to evaluate its efficacy and safety in humans, with the goal of developing an effective treatment for cognitive impairments.